Tenaya Therapeutics (TNYA) Common Equity (2020 - 2026)

Tenaya Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $106.2 million for Q1 2026.

• On a quarterly basis, Common Equity fell 11.06% year-over-year to $106.2 million in Q1 2026; TTM through Mar 2026 was $106.2 million, a 11.06% decrease from a year earlier, with the FY2025 full-year figure at $123.3 million, up 32.75% from the prior year.
• Common Equity retreated to $106.2 million in Q1 2026 per TNYA's latest filing, from $123.3 million in the prior quarter.
• Across five years, Common Equity topped out at $249.1 million in Q1 2022 and bottomed at $82.9 million in Q3 2025.
• The 5-year median for Common Equity is $139.4 million (2023), against an average of $156.0 million.
• Across the five-year window, Common Equity soared 365.16% in 2022 and slumped 42.71% in 2023, its largest moves.
• Year by year, Common Equity stood at $243.4 million in 2022, then slumped by 42.71% to $139.4 million in 2023, then slumped by 33.4% to $92.9 million in 2024, then surged by 32.75% to $123.3 million in 2025, then dropped by 13.85% to $106.2 million in 2026.
• Per Business Quant, the three latest TNYA Common Equity figures stand at $106.2 million (Q1 2026), $123.3 million (Q4 2025), and $82.9 million (Q3 2025).